<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35532152</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization.</ArticleTitle>
        <Pagination>
          <StartPage>1447</StartPage>
          <EndPage>1456</EndPage>
          <MedlinePgn>1447-1456</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2072541</ELocationID>
        <Abstract>
          <AbstractText>Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>, ATO) has limited therapeutic benefit to treat solid tumors, whether used alone or in combination. Nanoscale drug delivery vehicles have great potential to overcome the limitation of the utility of ATO by rapid renal clearance and dose-limiting toxicity. Polymeric materials ranging from gelatin foam to synthetic polymers such as poly(vinyl alcohol) were developed for vascular embolic or chemoembolic applications. Recently, we have introduced sevelamer, an oral phosphate binder, as a new polymeric embolic for vascular interventional therapy. In this paper, sevelamer arsenite nanoparticle with a polygonal shape and a size of 50-300 nm, synthesized by anionic exchange from sevelamer chloride, was developed as a Pi-responsive bifunctional drug carrier and embolic agent for chemoembolization therapy. At the same arsenic dosage, sevelamer arsenite-induced severer tumor necrosis than ATO on the VX2 cancer model. <i>In vitro</i> tests evidenced that Pi deprivation by sevelamer could enhance ATO's anticancer effect. The results showed that ATO in Pi starvation reduced cell viability, induced more apoptosis, and diminished the mitochondrial membrane potential (Δψm) of cells since Pi starvation helps ATO to further down-regulate Bcl-2 expression, up-regulate Bax expression, enhance the activation of caspase-3 and increase the release of cytochrome c, and the production of excessive reactive oxygen species (ROS). Sevelamer arsenite not only plays a Pi-activated nano-drug delivery system but also integrated anticancer drug with embolic for interventional therapy. Therefore, our results presented a new administration route of ATO as well as an alternative chemoembolization therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bi</LastName>
            <ForeName>Qiu-Chen</ForeName>
            <Initials>QC</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Advanced Study, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jian-Jun</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yang-Feng</ForeName>
            <Initials>YF</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Advanced Study, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Zhi-Qiang</ForeName>
            <Initials>ZQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First People's Hospital of Fuzhou, Fuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yu-Hua</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Interventional Radiology, Jiang Xi Province Chest Hospital, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Chuan-Sheng</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Qing-Rong</ForeName>
            <Initials>QR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Rong-Guang</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Imaging and Interventional Radiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Qun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Advanced Study, Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018053">Arsenites</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9YCX42I8IU</RegistryNumber>
          <NameOfSubstance UI="D000069603">Sevelamer</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001152" MajorTopicYN="Y">Arsenicals</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018053" MajorTopicYN="Y">Arsenites</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069603" MajorTopicYN="N">Sevelamer</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Arsenic trioxide</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">sevelamer</Keyword>
        <Keyword MajorTopicYN="N">transarterial chemoembolization</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>8</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35532152</ArticleId>
        <ArticleId IdType="pmc">PMC9103487</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2072541</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahn RW, Chen F, Chen H, et al.  (2010). A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res
16:3607–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2943376</ArticleId>
            <ArticleId IdType="pubmed">20519360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asghar U, Meyer T. (2012). Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
J Hepatol
56:686–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21971559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi QC, Luo RG, Li YS, et al.  (2022). Low inorganic phosphate stress inhibits liver cancer progression: from in vivo to in vitro. Adv Ther
5:2100224.</Citation>
        </Reference>
        <Reference>
          <Citation>Bobko AA, Eubank TD, Driesschaert B, et al.  (2017). Interstitial inorganic phosphate as a tumor microenvironment marker for tumor progression. Sci Rep
7:41233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5259743</ArticleId>
            <ArticleId IdType="pubmed">28117423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boulin M, Guiu S, Chauffert B, et al.  (2011). Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs
22:741–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21487286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown RB, Razzaque MS. (2018). Phosphate toxicity and tumorigenesis. Biochim Biophys Acta Rev Cancer
1869:303–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29684520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ca H, Phan H, Yang LX. (2012). Improved chemotherapy for hepatocellular carcinoma. Anticancer Res
32:1379–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22493374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camalier CE, Young MR, Bobe G, et al.  (2010). Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res
3:359–70.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen H, Gu S, Dai H, et al.  (2017). Dihydroartemisinin sensitizes human lung adenocarcinoma A549 cells to arsenic trioxide via apoptosis. Biol Trace Elem Res
179:203–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28261759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chouhan S, Singh S, Athavale D, et al.  (2020). Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucose-dependent alterations in reactive oxygen species, P-glycoprotein and DKK4. J Biosci
45:97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32713860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dilda PJ, Hogg PJ. (2007). Arsenical-based cancer drugs. Cancer Treat Rev
33:542–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17624680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frion-Herrera Y, Diaz-Garcia A, Ruiz-Fuentes J, et al.  (2015). Brazilian green propolis induced apoptosis in human lung cancer A549 cells through mitochondrial-mediated pathway. J Pharm Pharmacol
67:1448–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26206395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu X, Li YS, Zhao J, et al.  (2020). Will arsenic trioxide benefit treatment of solid tumor by nano-encapsulation?
Mini Rev Med Chem
20:239–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31760930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hengartner MO. (2000). The biochemistry of apoptosis. Nature
407:770–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11048727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leu L, Mohassel L. (2009). Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm
66:1913–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19850784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Bruix J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology
37:429–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12540794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J, Chew EH, Holmgren A. (2007). Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A
104:12288–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1940330</ArticleId>
            <ArticleId IdType="pubmed">17640917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv XH, Wang CH, Xie Y. (2017). Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: a meta-analysis. J Gastroenterol Hepatol
32:1540–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28299819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin P, Wang P, Robinson A, et al.  (2011). Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Am J Kidney Dis
57:700–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21354682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Memon K, Kulik L, Lewandowski RJ, et al.  (2011). Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology
141:526–35.e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152626</ArticleId>
            <ArticleId IdType="pubmed">21664356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller WH, Schipper HM, Lee JS, et al.  (2002). Mechanisms of action of arsenic trioxide. Cancer Res
62:3893–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12124315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murgo AJ. (2001). Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist
6:22–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Rohwer N, Cramer T. (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat
14:191–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21466972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sapio L, Naviglio S. (2015). Inorganic phosphate in the development and treatment of cancer: a Janus Bifrons?
World J Clin Oncol
6:198–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4675902</ArticleId>
            <ArticleId IdType="pubmed">26677430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scudellari M. (2014). Drug development: try and try again. Nature
516:S4–S6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25470198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen ZX, Chen GQ, Ni JH, et al.  (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood
89:3354–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9129042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szegezdi E, Cahill S, Meyer M, et al.  (2006). TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer
94:398–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2361137</ArticleId>
            <ArticleId IdType="pubmed">16434995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Mohammad A, Berendt RT, et al.  (2016). Evaluation of the in vitro efficacy of sevelamer hydrochloride and sevelamer carbonate. J Pharm Sci
105:864–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26219932</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
